Category: Drugs

Home / Drugs

Categories

Glofitamab-gxbm is approved by FDA for selected relapsed or refractory large B-cell lymphomas

July 2023: The Food and Drug Administration gave accelerated approval to glofitamab-gxbm (Columvi, Genentech, Inc.) for relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (...

Olaparib with abiraterone and prednisone (or prednisolone) is approved by FDA for BRCA-mutated metastatic castration-resistant prostate cancer

July 2023: The Food and Drug Administration (FDA) approved olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) with abiraterone and prednisone (or prednisolone) for adults with deleterious or suspecte...

Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

July 2023: The Food and Drug Administration gave accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise spec...

Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer

March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant tre...

Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma

March 2023: Study Type : Interventional (Clinical Trial)Estimated Enrollment : 30 participantsAllocation: N/AIntervention Model: Sequential AssignmentIntervention Model Description: a "3+3" d...

A study of chimeric antigen receptor T lymphocytes (CAR-T) in the treatment of relapsed and refractory non-Hodgkin lymphoma

Detailed Description: This is a single-center, single-arm, open-label study. After meeting the eligibility criteria and enrolling on the trial, patients will undergo leukapheresis for collect...

Anti-BCMA CAR T-Cell therapy clinical trials for relapse/refractory Immune thrombocytopenia(R/R ITP)

March 2023: Immune thrombocytopenia (ITP) is a disorder that can lead to easy or excessive bruising and bleeding. Approximately two-thirds of patients achieve remission after/during first-line therap...

China to open borders for patients travelling for medical treatment

Beijing, March 14, 2023: There is good news for patients travelling to China for advanced cancer treatment and the latest therapies like CAR T-Cell therapy, Cilta Cel therapy, and even for clinical ...

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products....

Perspectives on cancer experiences with oncologist Dr. Willie Goffney

Feb 2023: Check out this tweet from the American Cancer Society that shares a conversation with Dr. Willie Goffney about her perspective on cancer. A tweet says, "Join Adam Lopez, host of Candid Conv...

Scan the code